A bioassay of @entity49443 for possible carcinogenicity was conducted by administering the test chemical in feed to Fischer 344 @entity35 and B6C3F1 @entity19 . Groups of 35 @entity35 of each sex were administered @entity49443 in the diet at one of two doses, either 10,000 or 20,000 ppm, for 103 weeks and then observed for 2 to 4 additional weeks. Matched controls consisted of 15 untreated @entity35 of each sex. All surviving @entity35 were killed at 105 to 107 weeks. Groups of 35 @entity19 of each sex were administered @entity49443 at one of two doses for 103 weeks and then observed for 4 or 5 additional weeks. Time-weighted average doses were 6,359 or 12,718 ppm. Matched controls consisted of 15 untreated @entity19 of each sex. All surviving @entity19 were killed at 107 or 108 weeks. Mean body weights of the dosed @entity35 and @entity19 of both sexes were lower than those of the corresponding matched controls throughout the study, and the @entity308 in weight were dose related. Except for the female @entity19 , sufficient numbers of animals survived long enough to be at risk for development of late-appearing @entity5 . In the @entity35 , the only @entity5 occurring with greater incidence in dosed than in matched-control animals was @entity1778 (males: matched controls 0/15, low-dose 10/35, high-dose 4/35; females: matched controls 0/14, low-dose 7/35, high-dose 4/34). Only the incidence in the low-dose males was statistically significant (P=0.018). All of these animals had undifferentiated (mononuclear cell) @entity1778 , which commonly occurs spontaneously in Fischer 344 @entity35 , except for two with @entity2214 . The incidence of combined @entity1778 and @entity706 in historical-control male @entity35 at this laboratory in the bioassay program to date is 24/235 (10.2%), which is higher than that in the matched controls. Thus, the incidence in the low-dose males cannot be clearly associated with administration of the test chemical. In the @entity19 , the only @entity5 that occurred at a higher incidence in dosed groups than in matched controls were @entity706 in the males, but the incidences were not statistically significant (matched controls 1/15, low-dose 9/35, high-dose 3/34). These types of lesions are found commonly in untreated B6C3F1 @entity19 . The incidence of @entity706 in the historical-control male @entity19 is 28/536 (5.2%). It is concluded that under the conditions of this bioassay, @entity49443 was not carcinogenic for either Fischer 344 @entity35 or B6C3F1 @entity19 .

Bioassay of XXXX for possible carcinogenicity.

@entity2214 :: ('MESH:D007945', 'Disease') :: ['lymphocytic leukemia'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressions'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphomas', 'lymphoma'] @entity49443 :: ('MESH:D000092', 'Chemical') :: ['acetohexamide'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasms', 'tumors'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity49443 :: (MESH:D000092,Chemical) :: ['acetohexamide']
